Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Research & Development (2020 - 2025)

Apellis Pharmaceuticals has reported Research & Development over the past 6 years, most recently at $74.2 million for Q4 2025.

  • Quarterly results put Research & Development at $74.2 million for Q4 2025, down 2.78% from a year ago — trailing twelve months through Dec 2025 was $295.9 million (down 9.68% YoY), and the annual figure for FY2025 was $295.9 million, down 9.68%.
  • Research & Development for Q4 2025 was $74.2 million at Apellis Pharmaceuticals, up from $68.2 million in the prior quarter.
  • Over the last five years, Research & Development for APLS hit a ceiling of $110.0 million in Q1 2023 and a floor of $67.0 million in Q2 2025.
  • Median Research & Development over the past 5 years was $85.6 million (2024), compared with a mean of $85.5 million.
  • Biggest five-year swings in Research & Development: soared 55.32% in 2021 and later tumbled 30.32% in 2023.
  • Apellis Pharmaceuticals' Research & Development stood at $78.2 million in 2021, then grew by 27.17% to $99.4 million in 2022, then crashed by 30.32% to $69.3 million in 2023, then grew by 10.21% to $76.4 million in 2024, then decreased by 2.78% to $74.2 million in 2025.
  • The last three reported values for Research & Development were $74.2 million (Q4 2025), $68.2 million (Q3 2025), and $67.0 million (Q2 2025) per Business Quant data.